## We claim:

5

- 1. A recombinant expression vector comprising one or more enhancers linked to the 5' end of a ubiquitin promoter operably linked to a DNA sequence encoding a therapeutic gene.
- 2. The recombinant expression vector of claim 1, wherein the ubiquitin promoter is isolated from a gene selected from the group consisting of human ubiquitin A, ubiquitin B and ubiquitin C.
- 3. The recombinant expression vector of claim 2, wherein the enhancer is selected from the group consisting of a cytomegalovirus (CMV) enhancer, an elongation factor 1-alpha enhancer; endothelial enhancers and liver-specific enhancers.
  - 4. The recombinant expression vector of claim 3, wherein the enhancer is a CMV enhancer.
  - 5. The recombinant expression vector of claim 4, wherein the expression vector has been altered to eliminate at least one CpG sequence present in the native sequences.
- 6. The recombinant expression vector of claim 4, wherein the ubiquitin promoter is isolated from human ubiquitin B.
  - 7. The recombinant expression vector of claim 4, wherein the therapeutic gene is selected from the group consisting of factor VIII, factor VIII, and factor IX.
- 8. The recombinant expression vector of claim 4, wherein the therapeutic gene is selected from
  the group consisting of glucocerebrosidase, alpha-galactosidase, acid alpha-glucosidase,
  alpha-n-acetylgalactosaminidase, acid sphingomyelinase and alpha-iduronidase.
  - 9. The recombinant expression vector of claim 4, wherein the therapeutic gene is selected from the group consisting of CFTR, dystrophin and alpha-1-antitrypsin.

- 10. A recombinant expression vector comprising a CMV enhancer linked to the 5' end of a promoter isolated from human ubiquitin B operably linked to a DNA sequence encoding alpha-galactosidase.
- 11. A recombinant expression vector comprising a CMV enhancer linked to the 5' end of a promoter isolated from human ubiquitin B operably linked to a DNA sequence encoding glucocerebrosidase.

5